Search Results

By Matthew Stenger  / Thursday, August 14, 2014 12:41 PM

ERSPC 13-Year Follow-up: Reduction in Prostate Cancer Mortality With PSA Screening, but High Overdiagnosis Rates Remain a Concern, Say Authors

The 13-year follow-up of the European Randomized Study of Screening for Prostate Cancer (ERSPC), reported by Schröder et al in The Lancet, showed that prostate-specific antigen (PSA) screening in men aged 55 to 69 years is associated with a 21% reduction in risk of prostate cancer mortality...